Impact of the PPAR-γ2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: Evidence from BENEDICT

Salvatore De Cosmo, Nicola Motterlini, Sabrina Prudente, Fabio Pellegrini, Roberto Trevisan, Antonio Bossi, Giuseppe Remuzzi, Vincenzo Trischitta, Piero Ruggenenti

Research output: Contribution to journalArticle

Abstract

OBJECTIVE - Cross-sectional studies found less microalbuminuria in type 2 diabetic patients with the Ala12 allele of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) Pro12Ala polymorphism. We prospectively evaluated the association between Pro12Ala polymorphism (rs1801282) and newonset microalbuminuria. RESEARCH DESIGN AND METHODS - Pro12Ala polymorphism was genotyped by TaqMan-based assay in genomic DNA of 1,119 consenting patients from BErgamo NEphrologic DIabetic Complications Trial (BENEDICT) - a prospective, randomized trial evaluating ACE inhibition effect on new-onset microalbuminuria (albuminuria 20-200 μg/min in at least two of three consecutive overnight urine collections in two consecutive visits) in hypertensive type 2 diabetes with albuminuria

Original languageEnglish
Pages (from-to)2920-2929
Number of pages10
JournalDiabetes
Volume58
Issue number12
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Peroxisome Proliferator-Activated Receptors
Albuminuria
Diabetes Complications
Angiotensin-Converting Enzyme Inhibitors
Type 2 Diabetes Mellitus
Urine Specimen Collection
Research Design
Cross-Sectional Studies
Alleles
DNA
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Impact of the PPAR-γ2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes : Evidence from BENEDICT. / De Cosmo, Salvatore; Motterlini, Nicola; Prudente, Sabrina; Pellegrini, Fabio; Trevisan, Roberto; Bossi, Antonio; Remuzzi, Giuseppe; Trischitta, Vincenzo; Ruggenenti, Piero.

In: Diabetes, Vol. 58, No. 12, 12.2009, p. 2920-2929.

Research output: Contribution to journalArticle

@article{6c951885967e497caad92ee0fc3fb807,
title = "Impact of the PPAR-γ2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: Evidence from BENEDICT",
abstract = "OBJECTIVE - Cross-sectional studies found less microalbuminuria in type 2 diabetic patients with the Ala12 allele of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) Pro12Ala polymorphism. We prospectively evaluated the association between Pro12Ala polymorphism (rs1801282) and newonset microalbuminuria. RESEARCH DESIGN AND METHODS - Pro12Ala polymorphism was genotyped by TaqMan-based assay in genomic DNA of 1,119 consenting patients from BErgamo NEphrologic DIabetic Complications Trial (BENEDICT) - a prospective, randomized trial evaluating ACE inhibition effect on new-onset microalbuminuria (albuminuria 20-200 μg/min in at least two of three consecutive overnight urine collections in two consecutive visits) in hypertensive type 2 diabetes with albuminuria",
author = "{De Cosmo}, Salvatore and Nicola Motterlini and Sabrina Prudente and Fabio Pellegrini and Roberto Trevisan and Antonio Bossi and Giuseppe Remuzzi and Vincenzo Trischitta and Piero Ruggenenti",
year = "2009",
month = "12",
doi = "10.2337/db09-0407",
language = "English",
volume = "58",
pages = "2920--2929",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "12",

}

TY - JOUR

T1 - Impact of the PPAR-γ2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes

T2 - Evidence from BENEDICT

AU - De Cosmo, Salvatore

AU - Motterlini, Nicola

AU - Prudente, Sabrina

AU - Pellegrini, Fabio

AU - Trevisan, Roberto

AU - Bossi, Antonio

AU - Remuzzi, Giuseppe

AU - Trischitta, Vincenzo

AU - Ruggenenti, Piero

PY - 2009/12

Y1 - 2009/12

N2 - OBJECTIVE - Cross-sectional studies found less microalbuminuria in type 2 diabetic patients with the Ala12 allele of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) Pro12Ala polymorphism. We prospectively evaluated the association between Pro12Ala polymorphism (rs1801282) and newonset microalbuminuria. RESEARCH DESIGN AND METHODS - Pro12Ala polymorphism was genotyped by TaqMan-based assay in genomic DNA of 1,119 consenting patients from BErgamo NEphrologic DIabetic Complications Trial (BENEDICT) - a prospective, randomized trial evaluating ACE inhibition effect on new-onset microalbuminuria (albuminuria 20-200 μg/min in at least two of three consecutive overnight urine collections in two consecutive visits) in hypertensive type 2 diabetes with albuminuria

AB - OBJECTIVE - Cross-sectional studies found less microalbuminuria in type 2 diabetic patients with the Ala12 allele of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) Pro12Ala polymorphism. We prospectively evaluated the association between Pro12Ala polymorphism (rs1801282) and newonset microalbuminuria. RESEARCH DESIGN AND METHODS - Pro12Ala polymorphism was genotyped by TaqMan-based assay in genomic DNA of 1,119 consenting patients from BErgamo NEphrologic DIabetic Complications Trial (BENEDICT) - a prospective, randomized trial evaluating ACE inhibition effect on new-onset microalbuminuria (albuminuria 20-200 μg/min in at least two of three consecutive overnight urine collections in two consecutive visits) in hypertensive type 2 diabetes with albuminuria

UR - http://www.scopus.com/inward/record.url?scp=73249137608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73249137608&partnerID=8YFLogxK

U2 - 10.2337/db09-0407

DO - 10.2337/db09-0407

M3 - Article

C2 - 19720797

AN - SCOPUS:73249137608

VL - 58

SP - 2920

EP - 2929

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 12

ER -